Justin Klee (L) and Josh Cohen (Amylyx)
Adcomm votes 7-2 in favor of Amylyx's ALS drug on second take. But first the co-CEOs had to make a pledge
Second time’s the charm for Amylyx and its experimental ALS drug. In an unusual twist, outside experts on an FDA advisory committee voted 7-2 in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
